Biological E Gets CDSCO panel Nod for Post-marketing Surveillance study of Hepatitis B Vaccine
New Delhi: The Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has given its nod to the vaccine maker Biological E to conduct the Phase IV or Post-marketing Surveillance (PMS) study of the Hepatitis B Vaccine (rDNA) to evaluate the safety of Biological E’s monovalent recombinant Hepatitis B vaccine when administered to 6-8 weeks old infants in 6-10-14 weeks dosing schedule.
This came after the firm presented its proposal for a grant of permission to conduct a Phase IV/PMS study of the Hepatitis B Vaccine (rDNA) titled “A multicentre single-arm, Phase IV, post-marketing surveillance study to evaluate the safety of Biological E’s monovalent recombinant Hepatitis B vaccine when administered to 6-8 weeks old infants in 6-10-14 weeks dosing schedule”.
The Hepatitis B vaccine is indicated for active immunization against hepatitis B infection in subjects considered at risk of exposure to HBV-positive material.
Hepatitis B is a vaccine-preventable liver infection caused by the hepatitis B virus (HBV). Hepatitis B is spread when blood, semen, or other body fluids from a person infected with the virus enters the body of someone who is not infected.
Hepatitis B is a serious liver infection caused by the hepatitis B virus (HBV). For most people, hepatitis B is short-term, also called acute, and lasts less than six months. But for others, the infection becomes chronic, meaning it lasts more than six months. Having chronic hepatitis B increases your risk of developing liver failure, liver cancer, or cirrhosis — a condition that permanently scars the liver.
Most adults with hepatitis B recover fully, even if their symptoms are severe. Infants and children are more likely to develop a long-lasting hepatitis B infection. This is known as a chronic infection.
At the recent SEC meeting for Vaccine held on 27th June 2023, the expert panel reviewed the proposal for the grant of permission to conduct Phase IV/PMS study of Hepatitis B Vaccine (rDNA) titled “A multicentre single-arm, Phase IV, post-marketing surveillance study to evaluate the safety of Biological E’s monovalent recombinant Hepatitis B vaccine when administered to 6-8 weeks old infants in 6-10-14 weeks dosing schedule”.
After detailed deliberation, the committee recommended the conduct of a PMS study of the Hepatitis B Vaccine (rDNA) as per the presented protocol.
Accordingly, the expert panel suggested that the firm is required to revise the title and submit a revised protocol to CDSCO.
Also Read:J&J Gets CDSCO Panel Nod To Market Teclistamab sterile liquid in Vials
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.